How do recent AASLD/IDSA updates on HBV screening change nonspecialist and specialist management of HCV patients? Here’s my take.
Does the need for HBV reactivation screening vary by the potency of immunosuppressive therapy? Here’s my take.
In this CME-certified video module, Leonard H. Calabrese, DO; Robert P. Perrillo, MD, FAASLD; and Andrew D. Zelenetz, MD, PhD, discuss best practices in HBV screening and prophylaxis for patients who will undergo immunosuppressive therapy.
In this downloadable slideset, Leonard H. Calabrese, DO; Robert P. Perrillo, MD, FAASLD; and Andrew D. Zelenetz, MD, PhD, review HBV reactivation risk, screening, and prophylaxis for patients who will undergo immunosuppressive therapy.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.